Clinical trials: Adrenal Tumors
Adrenocortical Carcinoma
The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
This work will evaluate the adverse effects of mitotane treatment in patients treated for ACC with mitotane therapy. All of the individuals were treated at Ruijin Hospital between May 2023 and May 2024.
- Trial name
- MEET (NCT05839886)
- Volunteers
- 50 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Primary Aldosteronism, Adrenal Cushing Syndrome
Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death
Sudden Cardiac Death is a leading cause of mortality and remains a major public health burden worldwide. Cardiac arrest due to coronary heart disease explains a large proportion of the cases, but if autopsy is not performed the…
- Conditions
- Primary Aldosteronism, Adrenal Cushing Syndrome, Pheochromocytoma, Endocrine Neoplasia
- Trial name
- SuddenDeath (NCT05446779)
- Testing
- Adrenal aldosterone synthase (CYP11B2) staining, Adrenal cortisol synthase (CYP11B1) staining, Histopathological analysis
- Where
- Finland
- Volunteers
- 400 people
- Sponsor
- Helsinki University Central Hospital
Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
- Trial name
- NCT02592356
- Testing
- Computed Tomography, Dual X-ray Absorptiometry, Physical Examination
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Aldosteronism, Adrenal Adenoma
Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism
The aim of the study is to evaluate the novel use of adrenal radiofrequency ablation on a prospective cohort of patients with primary aldosteronism and unilateral adrenal adenoma concerning the efficacy on blood pressure control.
- Trial name
- ADERADHTA (NCT02756754)
- Testing
- Radiofrequency ablation
- Where
- 2 sites in France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Toulouse
Renal Carcinoma, Nephrectomy / Methods
R.E.C.K vs Exparel in Robotic Nephrectomy
The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial.
- Conditions
- Renal Carcinoma, Nephrectomy / Methods, Pain Management
- Trial name
- NCT07092566
- Testing
- Ropivacaine HCL, Exparel, Epinephrine
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Wake Forest University Health Sciences
Adrenal Cortical Carcinoma
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection
Patients who have no response to preoperative chemotherapy and no residual disease following surgery on Regimen A are treated on Regimen B postoperatively.
- Trial name
- NCT00001339
- Testing
- doxorubicin, vincristine, and etoposide with mitotane
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Adrenal Disease, Renal Cancer
Complication in Laparoscopic Renal and Adrenal Surgery (CLARAS)
the aim of this study is clarify complication and their resolution in laparoscopic renal and adrenal surgery.
- Conditions
- Adrenal Disease, Renal Cancer, Surgery--Complications
- Trial name
- CLARAS (NCT05322265)
- Testing
- laparoscopic surgery for renal and adrenal diseases
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- University of Palermo
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic Carcinoma in the Adrenal Cortex, Recurrent Adrenal Cortex Carcinoma
Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
The primary objective will be to assess overall response rate of nivolumab in patients with metastatic or locally advanced adrenocortical carcinoma. Nivolumab was recently approved by U.S.
- Conditions
- Metastatic Carcinoma in the Adrenal Cortex, Recurrent Adrenal Cortex Carcinoma, Stage III Adrenal Cortex Carcinoma, Stage IV Adrenal Cortex Carcinoma
- Trial name
- NCT02720484
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Adrenocortical Carcinoma, Pheochromocytoma
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ACC or PPGL.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT07743138
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well gossypol acetic acid works in treating patients with recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by surgery.
- Conditions
- Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
- Trial name
- NCT00848016
- Testing
- R-(-)-gossypol acetic acid
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
10% of patients with hypertension potentially have the treatable condition - primary aldosteronism (PA). This is caused by either bilateral adrenal disease (~40%), managed with lifelong medications; or unilateral disease (~60%)…
- Conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, Adrenal Tumors
- Trial name
- NCT06100367
- Testing
- 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
- Where
- 7 sites in Singapore
- Volunteers
- 97 people
- Sponsor
- Changi General Hospital
Pheochromocytoma, Cardiovascular Complication
Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors
Pheochromocytoma is an adrenomedullary chromaffin cell tumour that releases catecholamines. Adverse cardiovascular events are considered the main cause of morbidity and mortality in patients with pheochromocytoma.
- Conditions
- Pheochromocytoma, Cardiovascular Complication, Adrenal Incidentaloma
- Trial name
- HEMODYNAMICS (NCT07200245)
- Testing
- adrenalectomy
- Where
- France
- Volunteers
- 522 people
- Sponsor
- Central Hospital, Nancy, France
Adrenocortical Carcinoma, Pheochromocytoma
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- Spencer (NCT04187404)
- Testing
- EO2401, Nivolumab
- Where
- 12 sites in United States, Denmark and 6 more
- Volunteers
- 70 people
- Sponsor
- Enterome
Adrenal Gland Neoplasm
Study of Adrenal Gland Tumors
The adrenal glands, located atop the kidneys, normally produce several types of hormones. Tumors of these glands may or may not secrete hormones.
- Trial name
- NCT00005927
- Where
- United States
- Volunteers
- 690 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
This phase III clinical trial is studying how well cisplatin-based chemotherapy and/or surgery works in treating young patients with stage I, stage II, stage III or stage IV adrenocortical cancer.
- Conditions
- Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7
- Trial name
- NCT00304070
- Testing
- Cisplatin, Conventional Surgery, Doxorubicin Hydrochloride
- Where
- 91 sites in United States, Australia and 2 more
- Volunteers
- 78 people
- Sponsor
- Children's Oncology Group
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
This phase I/II trial studies the side effects of anti-CTLA4-NF monoclonal antibody (mAb) (BMS986218), nivolumab, and stereotactic body radiation therapy in treating patients with solid malignancies that has spread to other…
- Conditions
- Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm, Malignant Adrenal Gland Neoplasm, Metastatic Liver Carcinoma
- Trial name
- NCT04785287
- Testing
- Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Adrenocortical Carcinoma, Breast Cancer
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT00003038
- Testing
- doxorubicin hydrochloride, suramin
- Where
- United States
- Sponsor
- Mayo Clinic